Compare HERE & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HERE | RANI |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.1M | 106.9M |
| IPO Year | 2022 | 2021 |
| Metric | HERE | RANI |
|---|---|---|
| Price | $1.90 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 17.0K | ★ 650.2K |
| Earning Date | 06-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,633,000.00 |
| Revenue This Year | N/A | $274.77 |
| Revenue Next Year | $79.29 | $79.44 |
| P/E Ratio | $2.83 | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $1.50 | $0.45 |
| 52 Week High | $5.80 | $3.87 |
| Indicator | HERE | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 57.04 |
| Support Level | $1.81 | $0.73 |
| Resistance Level | $1.95 | $0.94 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 85.37 | 58.91 |
Here Group Ltd is dedicated to creating collectible pop toys that evoke joy and emotional resonance. The group design and compelling storytelling, which provide users with a collecting experience that blends artistic value with emotional warmth, continuously convey a joyful and immersive brand culture. Adhering to the brand philosophy of joy, integrity, wonder, and co-creation, the company is building a vibrant ecosystem connecting creativity and emotion, working hand-in-hand with overall toy enthusiasts to create, share, and transmit dreams.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.